Abstract
The use of psychotropic drugs in clinical psychiatry began in the late nineteenth century, changing the goal of treatment of mental illness from symptom improvement to social functioning. Psychotropic drugs are still widely used today. Clinicians prescribe the right drug, in the right dose, and in the right manner to the right patient population to lead them to recovery. This goal requires a proper patient-provider relationship, accurate diagnosis, and appropriate drug selection. Understanding the effects and side effects of drug administration requires knowledge of adherence, pharmacokinetics, pharmacodynamics, and pharmacogenomics. Pharmacokinetics is affected by processes such as drug administration, absorption, distribution, metabolism, and exertion, and is colored by environmental and genetic factors such as aging, comorbidities, and concomitant use of other drugs. Knowledge of these factors is necessary. In order to establish an appropriate patient-provider relationship, it is necessary to understand the concept of evidence-based treatment planning and shared decision making (SDM) when making treatment decisions with patients. Finally, after drug administration, evaluation and monitoring of efficacy, adverse drug reaction, and side effects are necessary. This chapter aims to summarize the basic knowledge required for effective pharmacotherapy, which will ultimately contribute to effective and safe pharmacotherapy.
References
Alexanderson, B., Evans, D. A., & Sjöqvist, F. (1969). Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. British Medical Journal, 4(5686), 764–768. https://doi.org/10.1136/bmj.4.5686.764
American Geriatrics Society. (2019). Updated AGS beers criteria® for potentially inappropriate medication use in older adults. (2019). Journal of the American Geriatrics Society, 67(4), 674–694. https://doi.org/10.1111/jgs.15767
Aparasu, R. R., Mort, J. R., & Brandt, H. (2003). Psychotropic prescription use by community-dwelling elderly in the United States. Journal of the American Geriatrics Society, 51(5), 671–677. https://doi.org/10.1034/j.1600-0579.2003.00212.x
Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., … Lundberg, J. (2019). Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: A PET study using [18F]FMeNER-D2. The International Journal of Neuropsychopharmacology, 22(4), 278–285. https://doi.org/10.1093/ijnp/pyz003.
Ban, T. A. (2001). Pharmacotherapy of mental illness – A historical analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25(4), 709–727. https://doi.org/10.1016/s0278-5846(01)00160-9
Beck, C. A., Williams, J. V., Wang, J. L., Kassam, A., El-Guebaly, N., Currie, S. R., .… Patten, S. B. (2005). Psychotropic medication use in Canada. Canadian Journal of Psychiatry, 50(10), 605–613. https://doi.org/10.1177/070674370505001006.
Beitinger, R., Kissling, W., & Hamann, J. (2014). Trends and perspectives of shared decision-making in schizophrenia and related disorders. Current Opinion in Psychiatry, 27(3), 222–229. https://doi.org/10.1097/yco.0000000000000057
Benet, L. Z., & Hoener, B. A. (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther, 71(3), 115–21. https://doi.org/10.1067/mcp.2002.121829. PMID: 11907485.
Bouvy, J. C., De Bruin, M. L., & Koopmanschap, M. A. (2015). Epidemiology of adverse drug reactions in Europe: A review of recent observational studies. Drug Safety, 38(5), 437–453. https://doi.org/10.1007/s40264-015-0281-0
Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., & Pirmohamed, M. (2009). Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One, 4(2), e4439. https://doi.org/10.1371/journal.pone.0004439
de Greef, R., Maloney, A., Olsson-Gisleskog, P., Schoemaker, J., & Panagides, J. (2011). Dopamine D2 occupancy as a biomarker for antipsychotics: Quantifying the relationship with efficacy and extrapyramidal symptoms. The AAPS Journal, 13(1), 121–130. https://doi.org/10.1208/s12248-010-9247-4
Furukawa, T. A., Cipriani, A., Leucht, S., Atkinson, L. Z., Ogawa, Y., Takeshima, N., . . . Salanti, G. (2018). Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evidence-Based Mental Health, 21(1), 1–3. https://doi.org/10.1136/eb-2017-102827.
Guillot, J., Maumus-Robert, S., Marceron, A., Noize, P., Pariente, A., & Bezin, J. (2020). The burden of potentially inappropriate medications in chronic polypharmacy. Journal of Clinical Medicine, 9(11). https://doi.org/10.3390/jcm9113728
Guyatt, G., Rennie, D., Meade, M. O., & Cook, D. J. (2014). Users’ guides to the medical literature: A manual for evidence-based clinical practice (3rd ed.). McGraw-Hill Education.
Hasan, A., Bandelow, B., Yatham, L. N., Berk, M., Falkai, P., Möller, H. J., & Kasper, S. (2019). WFSBP guideline task force chairs. WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry, 20(1), 2–16. https://doi.org/10.1080/15622975.2018.1557346. Epub 2019 Feb 4. PMID: 30526182.
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology, 62(12), 1049–1053. https://doi.org/10.1007/s00228-006-0209-9
Hiemke, C., Bergemann, N., Clement, H. W., Conca, A., Deckert. J., Domschke, K., et al. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 51(1–02), 9–62. https://doi.org/10.1055/s-0043-116492. Epub 2017 Sep 14. Erratum in: Pharmacopsychiatry. 2018 Jan;51(1–02):e1. PMID: 28910830.
Institute of Medicine Committee on Quality of Health Care in, A. (2000). In L. T. Kohn, J. M. Corrigan, & M. S. Donaldson (Eds.), To err is human: Building a safer health system. National Academies Press (US). Copyright 2000 by the National Academy of Sciences. All rights reserved.
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. The American Journal of Psychiatry, 157, 514–520.
Kasper, S., Lerman, M. N., McQuade, R. D., Saha, A., Carson, W. H., Ali, M., et al. (2003). Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The International Journal of Neuropsychopharmacology, 6(4), 325–337. https://doi.org/10.1017/s1461145703003651
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018). Effectiveness of long-acting injectable vs Oral antipsychotics in patients with schizophrenia: A meta-analysis of prospective and retrospective cohort studies. Schizophrenia Bulletin, 44(3), 603–619. https://doi.org/10.1093/schbul/sbx090
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013). Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: A meta-analysis. Journal of Clinical Psychopharmacology, 33(5), 675–681. https://doi.org/10.1097/JCP.0b013e3182983ffa
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209–1223. https://doi.org/10.1056/NEJMoa051688
Lotrich, F. E., & Pollock, B. G. (2005). Aging and clinical pharmacology: Implications for antidepressants. Journal of Clinical Pharmacology, 45(10), 1106–1122. https://doi.org/10.1177/0091270005280297
Marcum, Z. A., Amuan, M. E., Hanlon, J. T., Aspinall, S. L., Handler, S. M., Ruby, C. M., & Pugh, M. J. (2012). Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. Journal of the American Geriatrics Society, 60(1), 34–41. https://doi.org/10.1111/j.1532-5415.2011.03772.x
Medicine, I. O. (2011). Clinical practice guidelines we can trust. The National Academies Press.
Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67(1), 26–36. https://doi.org/10.1001/archgenpsychiatry.2009.175
Myer, N. M., Boland, J. R., & Faraone, S. V. (2018). Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Molecular Psychiatry, 23(9), 1929–1936. https://doi.org/10.1038/mp.2017.234
Nemeroff, C. B., DeVane, C. L., & Pollock, B. G. (1996). Newer antidepressants and the cytochrome P450 system. The American Journal of Psychiatry, 153(3), 311–320. https://doi.org/10.1176/ajp.153.3.311
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., et al. (2008). The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. The American Journal of Psychiatry, 165(2), 203–213. https://doi.org/10.1176/appi.ajp.2007.07010042
Phillips, J., Beam, S., Brinker, A., Holquist, C., Honig, P., Lee, L. Y., & Pamer, C. (2001). Retrospective analysis of mortalities associated with medication errors. American Journal of Health-System Pharmacy, 58(19), 1835–1841. https://doi.org/10.1093/ajhp/58.19.1835
Rodrigues, M. C., & Oliveira, C. (2016). Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: An integrative review. Revista Latino-Americana de Enfermagem, 24, e2800. https://doi.org/10.1590/1518-8345.1316.2800
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., . . . Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/appi.ajp.163.11.1905.
Sachs, G. S., Thase, M. E., Otto, M. W., Bauer, M., Miklowitz, D., Wisniewski, S. R., . . . Rosenbaum, J. F. (2003). Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry, 53(11), 1028–1042. https://doi.org/10.1016/s0006-3223(03)00165-3.
Snowdon, J., Day, S., & Baker, W. (2006). Current use of psychotropic medication in nursing homes. International Psychogeriatrics, 18(2), 241–250. https://doi.org/10.1017/s1041610205002449
Stovell, D., Morrison, A. P., Panayiotou, M., & Hutton, P. (2016). Shared treatment decision-making and empowerment-related outcomes in psychosis: Systematic review and meta-analysis. The British Journal of Psychiatry, 209(1), 23–28. https://doi.org/10.1192/bjp.bp.114.158931
Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet, 374, 620–627.
Tune, L. E. (2000). Serum anticholinergic activity levels and delirium in the elderly. Seminars in Clinical Neuropsychiatry, 5(2), 149–153. https://doi.org/10.153/SCNP00500149.
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002). Placebo response in studies of major depression: Variable, substantial, and growing. JAMA, 287(14), 1840–1847. https://doi.org/10.1001/jama.287.14.1840
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886–891. https://doi.org/10.1176/appi.ps.55.8.886
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Inada, K., Yamawaki, S., Kanba, S., Shinozaki, G., Kasper, S. (2023). General Principles of Pharmacologic Therapy. In: Tasman, A., et al. Tasman’s Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-42825-9_128-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-42825-9_128-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-42825-9
Online ISBN: 978-3-030-42825-9
eBook Packages: Springer Reference MedicineReference Module Medicine